Improving cancer treatment for triple negative breast cancer using STING agonists
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer
This study is looking at how to make a new type of cancer treatment work better for people with triple negative breast cancer by understanding how certain genes affect the treatment, so patients can have more effective options tailored to their specific needs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11059214 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of STING agonists, a type of immunotherapy, specifically for patients with triple negative breast cancer (TNBC). The researchers aim to understand how certain genetic factors, like the loss of PTEN, affect the response to these therapies. By preventing the degradation of STING and improving how these drugs are delivered to tumors, the study seeks to boost the immune response against TNBC. Patients may benefit from more effective treatment options that target their specific cancer characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple negative breast cancer, particularly those with PTEN loss.
Not a fit: Patients with other types of breast cancer or those whose tumors do not exhibit PTEN loss may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with triple negative breast cancer.
How similar studies have performed: Previous research has shown promise in using STING agonists for cancer treatment, indicating that this approach may be effective.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Barbie, Thanh Uyen — Dana-Farber Cancer Inst
- Study coordinator: Barbie, Thanh Uyen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.